Symbols / XBIO Stock $3.05 -1.29% Xenetic Biosciences, Inc.

Healthcare • Biotechnology • United States • NCM
XBIO (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. James F. Parslow
Exch · Country NCM · United States
Market Cap 6.99M
Enterprise Value -887.80K
Income -2.68M
Sales 2.98M
FCF (ttm) -1.38M
Book/sh 3.23
Cash/sh 3.44
Employees 2
Insider 10d —
IPO Jun 30, 2016
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -4.62
PEG —
P/S 2.35
P/B 0.95
P/C —
EV/EBITDA —
EV/Sales -0.30
Quick Ratio 8.14
Current Ratio 8.32
Debt/Eq 0.09
LT Debt/Eq —
EPS (ttm) -1.58
EPS next Y -0.66
EPS Growth —
Revenue Growth 18.10%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-03-12
Earnings (prior) 2026-03-12
ROA -23.21%
ROE -40.00%
ROIC —
Gross Margin 100.00%
Oper. Margin -81.30%
Profit Margin -90.07%
Shs Outstand 2.29M
Shs Float 1.78M
Insider Own 10.24%
Instit Own 10.28%
Short Float 0.68%
Short Ratio 0.71
Short Interest 14.88K
52W High 13.93
vs 52W High -78.10%
52W Low 1.90
vs 52W Low 60.53%
Beta 2.21
Impl. Vol. —
Rel Volume 0.35
Avg Volume 22.65K
Volume 7.95K
Target (mean) —
Tgt Median —
Tgt Low —
Tgt High —
# Analysts —
Recom None
Prev Close $3.09
Price $3.05
Change -1.29%
About

Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies to treat cancers. Its DNase technology targets neutrophil extracellular traps (NETS), which are involved in cancer growth, metastasis, and progression, and contribute to immunotherapy, chemotherapy, and radiotherapy resistance. The company's product pipeline includes XBIO-015 for the treatment of pancreatic carcinoma and solid tumors; XBIO-020 for the treatment of solid tumors; and ErepoXen, which uses PolyXen platform technology for the treatment of anemia in chronic kidney disease (CKD) patients. It has a sublicensing agreement with Takeda Pharmaceutical Co. Ltd, as well as various research, development, license and supply agreements with Serum Institute of India, PJSC Pharmsynthez, and SynBio, LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
—
Mean price target
2. Current target
$3.05
Latest analyst target
3. DCF / Fair value
$-10.87
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$3.05
Low
—
High
—
Mean
—

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2025-04-09 reit HC Wainwright & Co. Neutral → Neutral —
2025-03-20 reit HC Wainwright & Co. Neutral → Neutral —
2024-12-05 reit HC Wainwright & Co. Neutral → Neutral —
2024-11-22 reit HC Wainwright & Co. — → Neutral —
2024-08-20 reit HC Wainwright & Co. — → Neutral —
2023-05-16 down HC Wainwright & Co. Buy → Neutral —
News
RSS: Latest XBIO news
Insider Transactions

No recent insider transactions.

Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
2.98
+19.04%
2.50
-1.56%
2.54
+48.80%
1.71
Operating Revenue
2.98
+19.04%
2.50
-1.56%
2.54
+48.80%
1.71
Operating Expense
5.81
-13.33%
6.70
-4.97%
7.06
-16.25%
8.42
Research And Development
3.07
-6.78%
3.29
-5.91%
3.49
-26.75%
4.77
Selling General And Administration
2.75
-19.64%
3.42
-4.06%
3.56
-2.55%
3.65
General And Administrative Expense
2.75
-19.64%
3.42
-4.06%
3.56
-2.55%
3.65
Other Gand A
2.75
-19.64%
3.42
-4.06%
3.56
-2.55%
3.65
Total Expenses
5.81
-13.33%
6.70
-4.97%
7.06
-16.25%
8.42
Operating Income
-2.83
+32.58%
-4.20
+6.89%
-4.52
+32.78%
-6.72
Total Operating Income As Reported
-2.83
+32.58%
-4.20
+6.89%
-4.52
+32.78%
-6.72
EBITDA
-2.83
+32.58%
-4.20
+6.89%
-4.52
+32.51%
-6.69
Normalized EBITDA
-2.83
+32.58%
-4.20
+6.89%
-4.52
+32.51%
-6.69
Reconciled Depreciation
—
—
0.00
-100.00%
0.03
EBIT
-2.83
+32.58%
-4.20
+6.89%
-4.52
+32.78%
-6.72
Total Unusual Items
—
—
—
—
Total Unusual Items Excluding Goodwill
—
—
—
—
Special Income Charges
—
—
—
—
Impairment Of Capital Assets
—
—
—
—
Net Income
-2.68
+32.31%
-3.96
+4.22%
-4.13
+36.90%
-6.55
Pretax Income
-2.68
+32.31%
-3.96
+4.22%
-4.13
+36.90%
-6.55
Net Non Operating Interest Income Expense
0.15
-40.77%
0.25
-29.77%
0.36
+112.83%
0.17
Net Interest Income
0.15
-40.77%
0.25
-29.77%
0.36
+112.83%
0.17
Interest Income Non Operating
0.15
-40.77%
0.25
-29.77%
0.36
+112.83%
0.17
Interest Income
0.15
-40.77%
0.25
-29.77%
0.36
+112.83%
0.17
Other Income Expense
0.01
+200.30%
-0.01
-122.49%
0.03
+1689.23%
-0.00
Other Non Operating Income Expenses
0.01
+200.30%
-0.01
-122.49%
0.03
+1689.23%
-0.00
Tax Provision
—
—
—
—
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-2.68
+32.31%
-3.96
+4.22%
-4.13
+36.90%
-6.55
Net Income From Continuing Operation Net Minority Interest
-2.68
+32.31%
-3.96
+4.22%
-4.13
+36.90%
-6.55
Net Income From Continuing And Discontinued Operation
-2.68
+32.31%
-3.96
+4.22%
-4.13
+36.90%
-6.55
Net Income Continuous Operations
-2.68
+32.31%
-3.96
+4.22%
-4.13
+36.90%
-6.55
Normalized Income
-2.68
+32.31%
-3.96
+4.22%
-4.13
+36.90%
-6.55
Net Income Common Stockholders
-2.68
+32.31%
-3.96
+4.22%
-4.13
+36.90%
-6.55
Diluted EPS
-1.58
+38.52%
-2.57
+5.17%
-2.71
+41.21%
-4.61
Basic EPS
-1.58
+38.52%
-2.57
+5.17%
-2.71
+41.21%
-4.61
Basic Average Shares
1.70
+10.40%
1.54
+0.86%
1.53
+7.44%
1.42
Diluted Average Shares
1.70
+10.40%
1.54
+0.86%
1.53
+7.44%
1.42
Diluted NI Availto Com Stockholders
-2.68
+32.31%
-3.96
+4.22%
-4.13
+36.90%
-6.55
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
8.36
+21.19%
6.90
-34.92%
10.61
-27.96%
14.72
Current Assets
8.05
+22.20%
6.59
-31.29%
9.59
-29.78%
13.65
Cash Cash Equivalents And Short Term Investments
7.88
+27.87%
6.17
-31.36%
8.98
-31.41%
13.10
Cash And Cash Equivalents
7.88
+27.87%
6.17
-31.36%
8.98
-31.41%
13.10
Cash Financial
7.88
+27.87%
6.17
-31.36%
8.98
-31.41%
13.10
Prepaid Assets
—
—
—
0.56
Other Current Assets
0.17
-60.59%
0.42
-30.12%
0.60
+8.58%
0.56
Total Non Current Assets
0.31
+0.00%
0.31
-69.17%
1.02
-4.55%
1.07
Net PPE
—
—
—
—
Gross PPE
—
—
—
—
Accumulated Depreciation
—
—
—
—
Machinery Furniture Equipment
—
—
—
—
Other Non Current Assets
0.31
+0.00%
0.31
-69.17%
1.02
-4.55%
1.07
Total Liabilities Net Minority Interest
0.97
+8.25%
0.89
+10.46%
0.81
-24.56%
1.07
Current Liabilities
0.97
+8.25%
0.89
+10.46%
0.81
-24.56%
1.07
Payables And Accrued Expenses
0.94
+9.78%
0.86
+12.97%
0.76
-26.31%
1.03
Payables
0.26
-8.99%
0.28
+17.76%
0.24
-16.19%
0.29
Accounts Payable
0.26
-8.99%
0.28
+17.76%
0.24
-16.19%
0.29
Current Accrued Expenses
0.69
+19.01%
0.58
+10.75%
0.52
-30.21%
0.75
Other Current Liabilities
0.02
-30.20%
0.03
-29.12%
0.05
+20.79%
0.04
Total Non Current Liabilities Net Minority Interest
0.00
0.00
0.00
0.00
Stockholders Equity
7.40
+23.12%
6.01
-38.67%
9.80
-28.22%
13.65
Common Stock Equity
7.39
+23.13%
6.01
-38.68%
9.79
-28.22%
13.64
Capital Stock
0.00
+11.91%
0.00
+0.03%
0.00
-22.03%
0.00
Common Stock
0.00
+48.48%
0.00
+0.06%
0.00
+1.58%
0.00
Preferred Stock
0.00
-19.40%
0.00
+0.00%
0.00
-34.97%
0.00
Share Issued
2.29
+48.48%
1.54
+0.09%
1.54
+1.58%
1.52
Ordinary Shares Number
2.29
+48.56%
1.54
+0.09%
1.54
+1.58%
1.52
Treasury Shares Number
0.00
+0.00%
0.00
+0.00%
0.00
+0.07%
0.00
Additional Paid In Capital
212.29
+1.95%
208.23
+0.08%
208.05
+0.14%
207.77
Retained Earnings
-199.88
-1.36%
-197.19
-2.05%
-193.23
-2.19%
-189.10
Gains Losses Not Affecting Retained Earnings
0.25
+0.00%
0.25
+0.00%
0.25
+0.00%
0.25
Treasury Stock
5.28
+0.00%
5.28
+0.00%
5.28
+0.00%
5.28
Other Equity Adjustments
0.25
+0.00%
0.25
+0.00%
0.25
+0.00%
0.25
Total Equity Gross Minority Interest
7.40
+23.12%
6.01
-38.67%
9.80
-28.22%
13.65
Total Capitalization
7.40
+23.12%
6.01
-38.67%
9.80
-28.22%
13.65
Working Capital
7.08
+24.39%
5.69
-35.14%
8.78
-30.23%
12.58
Invested Capital
7.39
+23.13%
6.01
-38.68%
9.79
-28.22%
13.64
Net Tangible Assets
7.40
+23.12%
6.01
-38.67%
9.80
-28.22%
13.65
Tangible Book Value
7.39
+23.13%
6.01
-38.68%
9.79
-28.22%
13.64
Preferred Stock Equity
0.00
-19.40%
0.00
+0.00%
0.00
-34.97%
0.00
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-2.29
+18.84%
-2.82
+31.52%
-4.11
+11.46%
-4.65
Cash Flow From Continuing Operating Activities
-2.29
+18.84%
-2.82
+31.52%
-4.11
+11.46%
-4.65
Net Income From Continuing Operations
-2.68
+32.31%
-3.96
+4.22%
-4.13
+36.90%
-6.55
Depreciation Amortization Depletion
—
—
0.00
-100.00%
0.03
Depreciation
—
—
0.00
-100.00%
0.03
Depreciation And Amortization
—
—
0.00
-100.00%
0.03
Other Non Cash Items
—
—
—
1.79
Stock Based Compensation
0.06
-62.29%
0.17
-39.31%
0.28
-44.65%
0.51
Asset Impairment Charge
—
—
—
—
Deferred Tax
—
—
—
—
Deferred Income Tax
—
—
—
—
Change In Working Capital
0.33
-66.07%
0.97
+469.58%
-0.26
+38.43%
-0.43
Change In Prepaid Assets
0.26
+40.57%
0.18
+481.02%
-0.05
+53.99%
-0.10
Change In Payables And Accrued Expense
0.07
-12.89%
0.08
+132.13%
-0.26
+24.25%
-0.35
Change In Payable
0.07
-12.89%
0.08
+132.13%
-0.26
+24.25%
-0.35
Change In Account Payable
0.07
-12.89%
0.08
+132.13%
-0.26
+24.25%
-0.35
Change In Other Current Assets
0.00
-100.00%
0.70
+1350.07%
0.05
+94.32%
0.03
Investing Cash Flow
—
—
0.00
+100.00%
-0.50
Cash Flow From Continuing Investing Activities
—
—
0.00
+100.00%
-0.50
Capital Expenditure
—
—
—
-0.50
Net Intangibles Purchase And Sale
—
—
0.00
+100.00%
-0.50
Purchase Of Intangibles
—
—
0.00
+100.00%
-0.50
Financing Cash Flow
4.00
0.00
—
0.00
Cash Flow From Continuing Financing Activities
4.00
+400471400.00%
0.00
—
0.00
Net Common Stock Issuance
4.00
+400471400.00%
0.00
—
0.00
Proceeds From Stock Option Exercised
—
—
—
0.00
Net Other Financing Charges
—
-0.00
—
—
Changes In Cash
1.72
+160.98%
-2.82
+31.52%
-4.11
+20.06%
-5.15
Beginning Cash Position
6.17
-31.36%
8.98
-31.41%
13.10
-28.21%
18.24
End Cash Position
7.88
+27.87%
6.17
-31.36%
8.98
-31.41%
13.10
Free Cash Flow
-2.29
+18.84%
-2.82
+31.52%
-4.11
+20.06%
-5.15
Interest Paid Supplemental Data
0.00
0.00
0.00
0.00
Common Stock Issuance
4.00
+400471400.00%
0.00
—
0.00
Issuance Of Capital Stock
4.00
+400471400.00%
0.00
—
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category